Kidney condition in patients with spondyloarthritis receiving genetically engineered biologic drugs


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. Evaluation of the kidney condition in patients with spondyloarthritis (SpA) who received therapy with genetically engineered biological drugs (GEBDs) for a year. material and methods. an analysis of the disease activity and the kidney condition in 18 spa patients who received gebds for a year was performed. results. Against the background of the 1-year use of gebds, a significant decrease in glomerular filtration rate with a normal serum creatinine level was noted. the frequency of glucocorticoid administration has been reduced during the treatment with gebds. the importance of early diagnosis of kidney damage and the timely initiation of therapy with gebds in spa patients has been demonstrated. Conclusion. timely prescribing of gebds in most cases allows achieving better control of the spa activity and preventing or reducing the severity of developing complications, including kidney damage. further evaluation of the gebd effect of on renal function is required.

Full Text

Restricted Access

About the authors

K. D Dorogoykina

Saratov State Medical University named after V.l. Razumovsky

Email: dorogoykinakd@mail.ru
Postgraduate Student at the Department of Hospital Therapy, Faculty of Medicine Saratov, Russia

D. S Sedov

Saratov State Medical University named after V.l. Razumovsky

Email: 77sedov77@mail.ru
Postgraduate Student at the Department of Hospital Therapy, Faculty of Medicine Saratov, Russia

K. A Gamayunova

Saratov State Medical University named after V.l. Razumovsky

Email: k.a.gamayunova@mail.ru
Postgraduate Student at the Department of Hospital Therapy, Faculty of Medicine Saratov, Russia

A. P Rebrov

Saratov State Medical University named after V.l. Razumovsky

Email: andreyrebrov@yandex.ru
Doctor of Medical Sciences, Professor, Head of the Department of Hospital Therapy, Faculty of Medicine Saratov, Russia

References

  1. Couderc M, Pereira B., Molto A., et al. The Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from the International ASAS-COMOSPA Study. J. Rheumatol. 2018;45(6):795-801. doi: 10.3899/jrheum.170133.
  2. Моминова Г.Н., Кулымбетова Б.А., Султанбекова А.О. и др. Опыт применения генно-инженерных препаратов у пациента с анкилозирующим спон-дилоартритом, осложненным АА-амилоидозом почек. Вестник Казахского Национального медицинского университета. 2018;2:501-504.
  3. Муравьев Ю.В., Муравьева Л.А. Проблема лабораторного мониторинга при терапии базисными противовоспалительными и генно-инженерными биологическими препаратами у больных ревматоидным артритом. Современная ревматология. 2018; 12(3): 120-123
  4. Ota M., Iwai H., Imai K., et al. Acute Tubulointerstitial Nephritis Associated with Infliximab in a Patient with Crohn’s Disease. Intern Med. 2016;55:1367-1370. doi: 10.2169/internalmedicine.55.5834.
  5. Costa M.F., Said N.R., Zimmermann B. Drug-induced lupus due to antitumor necrosis factor a agents. Semin. Arthr. Rheum. 2008;37:381-387. doi: 10.1016/j.semarthrit.2007.08.003.
  6. Bhagat Singh A.K., Jeyaruban A.S., Wilson G.J., et al. Adalimumab-induced IgA nephropathy. BMJ Case Reports CP. 2019;12:e226442. Doi: 10.1136/ bcr-2018-226442.
  7. Yarkan Tugsal H., Zengin B., Kenar G., et al. Infliximab-associated focal segmental glomerulosclerosis in a patient with ankylosing spondylitis. Rheumatol. Int. 2019;39(3):561-567. doi: 10.1007/s00296-019-04241-8.
  8. Годзенко А.А. Поражение почек при серонегативных спондилоартритах. Трудный пациент. 2006;4(7):46-8.
  9. Barbouch S., Hajji M., Jaziri F., et al. Renal amyloidosis in ankylosing spondylitis: A monocentric study and review of literature. Saudi J. Kidney Dis. Transpl. 2018;29:386-391. doi: 10.4103/1319-2442.229291.
  10. Verschueren P., Lensen F., Lerut E. Benefit of anti-TNF-a treatmentfor nephritic syndrome in patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann. Rhem. Dis. 2003;62:368-369.
  11. Donmez S., Pamuk O.N., Pamuk G.E., et al. Secondary amyloidosis in ankylosing spondylitis. Rheumatol. Int. 2013;33(7):1725-1729. Doi: 10.1007/ s00296-012-2646-3.
  12. Lee Y.H., Kim E.Y., Jeong D.W. Complete Remission of Nephrotic Syndrome Without Resolution of Amyloid Deposit After Anti-Tumor Necrosis Factor a Therapy in a Patient With Ankylosing Spondylitis. J. Clin. Rheumatol. 2016;22(2):86-88. doi: 10.1097/RHU.0000000000000356.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies